Synergy Pharmaceuticals has revealed positive Phase IIa trial results for plecanatide, a new treatment for chronic constipation.
The double-blind, dose-escalation, randomised, placebo-controlled, cohort-design and multi-centre clinical trial evaluated the pharmacodynamic safety of the drug.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The findings showed that the patients who received plecanatide had improved bowel function, more frequent bowel movements and less abdominal discomfort.
Plecanatide also demonstrated an improved safety profile and no severe adverse events were observed.
The study enrolled 78 evaluable patients, who received a once-daily dose of placebo or plecanatide for 14 consecutive days at oral doses of 0.3mg, 1mg, 3mg or 9mg.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
